Late last week a study published in the The Lancet concluded;
“We stratified patients into five subgroups with differing disease progression and risk of diabetic complications. This new substratification might eventually help to tailor and target early treatment to patients who would benefit most, thereby representing a first step towards precision medicine in diabetes.”
Per an article posted on the FirstWord Pharma web site;
“Scientist Leif Groop remarked "this is extremely important, we're taking a real step towards precision medicine," adding "in the ideal scenario, this is applied at diagnosis and we target treatment better."
No disrespect to Leif . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.